Shares of Sun Pharma Advanced Research Company (SPARC) rise as much as 4.8 percent to Rs 404.9, biggest daily percent gain in nearly a week.
Pharma research & development co expects to file with US Food and Drug Administration its new drug application for cancer drug Taclantis by Q4 2019, it said here in a presentation on Tuesday.
Co says deadlines for U.S. FDA to review ocular hypertension drug Xelpros and anti-epileptic agent Elepsia as November 2018 and January 2019, respectively.
SPARC seems to be nearing monetization of its lead products, Morgan Stanley says in note.
Sun Pharmaceutical Industries should benefit from the potential FY 2019 commercialization of two mid-sized lead assets (Xelpros and Elepsia XR), Morgan Stanley adds.
SPARC was demerged from Sun Pharma in 2006, both firms share same parent.
Sun Pharma shares rise as much as 2.5 percent to Rs 671.8.
Also, catch all the action and updates in our Market Live blog.